Na₃ScF₆: 20% Yb³⁺, 2% Er³⁺ samples were synthesized with different reaction times and reaction temperatures using the solvothermal method. We carried out a series of tests on Na3ScF6 crystals. The XRD patterns showed that the monoclinic phases of the Na₃ScF₆ samples could be synthesized under different reaction conditions, and doping with Yb³⁺ ions and Er³⁺ ions did not change the crystal structures. The SEM images showed that the sizes of the samples gradually increased with reaction time and reaction temperature. The fluorescence spectra showed that the emission peaks of the prepared samples under 980 nm near-infrared (NIR) excitation were centered at 520 nm/543 nm and 654 nm, corresponding to the ²H_11/2/⁴S_3/2→⁴I_15/2 and ⁴F_9/2→⁴I_15/2 transitions, respectively. With the increasing size of the samples, the emission intensities at 654 nm increased and the luminescence colors changed from green to red; at the same time, the red-to-green luminescence intensity ratios (IR/IG ratios) increased from 0.435 to 15.106—by as much as ~34.7 times. Therefore, this paper provides a scheme for tuning the IR/IG ratios of Na₃ScF₆: 20% Yb³⁺, 2% Er³⁺ samples by changing their sizes, making it possible to enhance the intensity of red upconversion, which has great potential for the study of color displays and lighting.

Chronic hepatitis B (CHB) is a major global health issue. The role of rare genetic variants in CHB has not been elucidated. We aimed to identify rare allelic variants predisposing to CHB. We performed exome sequencing in 50 CHB patients who had no identifiable risk factors for CHB and 40 controls who were healthy and hepatitis B surface antibody-positive, but had never received hepatitis B vaccination. We selected six rare variant alleles and followed up their association with disease status by Sanger sequencing in a case-control study comprising 1,728 CHB patients and 1,636 healthy controls. The latter had either not been immunized with hepatitis B vaccine or had uncertain vaccination status. Our results showed that transmembrane protein 2 p.Ser1254Asn, interferon alpha 2 p.Ala120Thr, its regulator NLR family member X1 p.Arg707Cys, and complement component 2 p.Glu318Asp were associated with CHB, with P values of <1.0 × 10−7, 2.76 × 10−5, 5.08 × 10−5, 2.78 × 10−4 and odds ratios (ORs) of 2.45, 4.08, 2.34, and 1.97, respectively. The combined P value was <2.0 × 10−16. As there has been no indication of immunological functions for the associated gene, transmembrane protein 2 , we further studied its expression by immunohistochemistry, real-time polymerase chain reaction, and western blotting. Our results showed that it was strongly expressed by healthy hepatocytes, but its expression was reduced in liver tissues with CHB, hepatitis B viral (HBV) genome-containing HepG2.2.15 cells, as compared with healthy liver tissues and non-HBV genome-containing HepG2 cells ( P = 0.022 and 0.0036, respectively). Conclusion : We identified four missense mutations associated with CHB, our results providing evidence for rare inborn genetic defects that contribute to increased host susceptibility to CHB.